personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Bevacizumab treatment for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy (AOFVD)

Session Details

Session Title: Quick Fire Free Paper Session 01

Session Date/Time: Thursday 26/09/2013 | 08:30-10:30

Paper Time: 08:55

Venue: Hall G1 (Level 2)

First Author: L.Tiosano ISRAEL

Co Author(s):    T. Jaouni   E. Averbukh   M. Grunin   E. Banin     

Abstract Details

Purpose:

Adult-onset foveomacular vitelliform dystrophy (AOFVD) may be complicated by choroidal neovascularization (CNV). We aim to evaluate the response to anti-vascular endothelial growth factor (VEGF) therapy in AOFVD-associated CNV.

Setting:

A retrospective consecutive group of 11 eyes of 11 patients with AOFVD associated CNV were reviewed.

Methods:

Demographics, clinical characteristics, response to anti-VEGF therapy, and central foveal thickness (CFT) measurement in OCT were evaluated. Results were compared to 60 consecutive neovascular age related macular degeneration (AMD). Patients treated at the same clinic and time period using the same bevacizumab loading dose-PRN treatment algorithm.

Results:

Mean±SD of AOFVD and AMD patients age at time of presentation with CNV was 79.6±10.6 and 77±7.7, respectively (p=0.39). Mean LogMAR visual acuity at presentation in AOFVD and AMD was 0.7±0.8 and 1±0.75, respectively, while mean final visual acuity was 0.87±0.7 vs. 1±0.85 in AOFVD and AMD, respectively (p=0.74). Mean follow-up time was 25.4±16.9 months in AOFVD and 27±7.8 months in AMD (p=0.64), and mean number of bevacizumab injections administered was 12.4±10.4 and 9±6.7 in AOFVD and AMD, respectively (p=0.18). At the end of the follow-up period, visual acuity was improved in 3 eyes, stabilized in 1 eye, and deteriorated in 7 of the AOFVD eyes. Per OCT 10 eyes had vitelliruptive lesions and one eye had vitelliform lesion at presentation. At the end of the follow-up period, 7 eyes had vitilliruptive lesions and 4 eyes progressed to atrophy. Two of the AOFVD patients had typical drusen, 2 had cuticular drusen, and 1 had subretinal drusenoid deposits in addition to the vitelliform lesion. The Mean±SD CFT for AOFVD patients at presentation was 418±144 micron, and 330±64 micron at the end of the follow-up period (p<0.05).

Conclusions:

In this small group of AOFVD patients the central foveal thickness improved in AOFVD; however the final visual acuity outcome didn’t improve comparing to the AMD patients at the same treatment algorithm.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy